In the March 1, 2020 issue of JAIDS Journal of Acquired Immune Deficiency Syndromes, in the article titled “Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials,”1 there were errors in Supplementary Digital Content files 3, 4, 5, and 11.
The corrected Supplementary Digital Content files are available in the links below: https://links.lww.com/QAI/B472, https://links.lww.com/QAI/B473, https://links.lww.com/QAI/B474, and https://links.lww.com/QAI/B475.
1. Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of Dolutegravir Plus lamivudine in antiretroviral treatment–naive Adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical Trials. J Acquir Immune Defic Syndr. 2020;83:310–318.